IQVIA Holdings Inc. $IQV Shares Sold by TD Asset Management Inc

TD Asset Management Inc lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 15.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 99,507 shares of the medical research company’s stock after selling 17,770 shares during the quarter. TD Asset Management Inc’s holdings in IQVIA were worth $22,430,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in IQV. Brighton Jones LLC boosted its position in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC lifted its stake in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of IQVIA during the second quarter worth $514,000. First Trust Advisors LP grew its stake in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on IQV. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. HSBC set a $210.00 price target on shares of IQVIA in a research report on Wednesday. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research note on Thursday, May 7th. Finally, Truist Financial decreased their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA presently has an average rating of “Buy” and an average price target of $224.13.

IQVIA Price Performance

IQV stock opened at $183.56 on Monday. The business’s 50-day moving average is $172.12 and its two-hundred day moving average is $194.79. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market capitalization of $30.64 billion, a P/E ratio of 22.75, a P/E/G ratio of 1.57 and a beta of 1.21. IQVIA Holdings Inc. has a 1 year low of $147.62 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.